An electrophysiological basis for the antiarrhythmic actions of the kappa-opioid receptor agonist U-50,488H
- PMID: 7813552
- DOI: 10.1016/0014-2999(94)90121-x
An electrophysiological basis for the antiarrhythmic actions of the kappa-opioid receptor agonist U-50,488H
Abstract
This study examined the actions of the selective kappa-opioid receptor agonist, U-50,488H, on voltage activated Na+ and K+ currents in isolated rat cardiac myocytes. U-50,488H produced a concentration-dependent block of the transient Na+ current with an ED50 of about 15 microM, and, at higher concentrations (40-50 microM), a block of the plateau K+ current and an increase in the rate of decay of the transient K+ current. In addition U-50,488H produced a hyperpolarising shift in the inactivation curve for the transient Na+ current without altering the voltage dependence for activation and without an effect on the voltage dependence of inactivation or activation of K+ currents. The block of Na+ currents by U-50,488H showed pronounced use dependence. The kappa-opioid receptor antagonist MR2266 did not itself produce any change in the Na+ or K+ currents and did not change the channel blocking properties of U-50,488H. Thus, since the antiarrhythmic actions of U-50,488H are not blocked by MR2266 or naloxone, the effects of U-50,488H to block Na+ and K+ currents are the most likely reasons for its antiarrhythmic actions, rather than an action at kappa-opioid receptors.
Similar articles
-
Sodium channel-blocking properties of spiradoline, a kappa receptor agonist, are responsible for its antiarrhythmic action in the rat.J Cardiovasc Pharmacol. 1998 Dec;32(6):863-74. doi: 10.1097/00005344-199812000-00002. J Cardiovasc Pharmacol. 1998. PMID: 9869491
-
Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.Br J Pharmacol. 1992 Mar;105(3):521-6. doi: 10.1111/j.1476-5381.1992.tb09012.x. Br J Pharmacol. 1992. PMID: 1320979 Free PMC article.
-
Effects of U50,488H on transient outward and ultra-rapid delayed rectifier K+ currents in young human atrial myocytes.Eur J Pharmacol. 2003 Jul 25;473(2-3):97-103. doi: 10.1016/s0014-2999(03)01974-5. Eur J Pharmacol. 2003. PMID: 12892826
-
[New evolvement of antiarrhythmic drugs].Nihon Yakurigaku Zasshi. 1993 Sep;102(3):215-23. doi: 10.1254/fpj.102.215. Nihon Yakurigaku Zasshi. 1993. PMID: 8406233 Review. Japanese.
-
Antiarrhythmic drugs and cardiac ion channels: mechanisms of action.Prog Biophys Mol Biol. 1998;70(1):1-72. doi: 10.1016/s0079-6107(98)00002-9. Prog Biophys Mol Biol. 1998. PMID: 9785957 Review.
Cited by
-
Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker.Biomed Pharmacother. 2018 Oct;106:510-522. doi: 10.1016/j.biopha.2018.06.157. Epub 2018 Jul 11. Biomed Pharmacother. 2018. PMID: 29990839 Free PMC article.
-
Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.Med Res Rev. 2016 Sep;36(5):871-923. doi: 10.1002/med.21395. Epub 2016 May 16. Med Res Rev. 2016. PMID: 27197922 Free PMC article. Review.
-
Potent and use-dependent block of cardiac sodium channels by U-50,488H, a benzeneacetamide kappa opioid receptor agonist.Exp Clin Cardiol. 2001 Summer;6(2):61-71. Exp Clin Cardiol. 2001. PMID: 20428265 Free PMC article.
-
Molecular analysis of the Na+ channel blocking actions of the novel class I anti-arrhythmic agent RSD 921.Br J Pharmacol. 1999 May;127(1):9-18. doi: 10.1038/sj.bjp.0702488. Br J Pharmacol. 1999. PMID: 10369450 Free PMC article.
-
Sex differences in U50,488H-induced phosphorylation of p44/42 mitogen-activated protein kinase in the guinea pig brain.Neuroscience. 2012 Oct 25;223:447-56. doi: 10.1016/j.neuroscience.2012.07.040. Epub 2012 Jul 31. Neuroscience. 2012. PMID: 22863678 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources